Please assess the completion status of the following clinical trial:

Trial Title: Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Radioiodine-refractory metastatic or unresectable locally-advanced thyroid cancer~* At least 1 measurable target lesion, as defined by RECIST~Exclusion Criteria:~* Thyroid lymphoma~* Previous treatment with anti-angiogenesis agents~* No myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, deep vein thrombosis or pulmonary embolism within 12 months prior.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).